Ads
related to: dapagliflozin role in heart failure- Patient Coverage
Pay As Little As $10.
Search For Patient Coverage.
- Safety Data
Safety & Warning Info For HCPs.
Review Clinical Trail Data.
- Clinical Data
Clinical Trial Data For HCPs.
Learn More About JARDIANCE.
- Resources
Resources For You And Your Staff.
Resources For You & Your Patients.
- Patient Coverage
Search results
Results from the WOW.Com Content Network
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
GLP-1 agonists were developed initially for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonist or SGLT2 inhibitor as a first line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.
For premium support please call: 800-290-4726 more ways to reach us
Name, sponsor, role Description SOLOIST, Sanofi Lexicon, Chair [15] Randomized controlled clinical trial (RCT) of sotagliflozin versus placebo in patients with diabetes and acute decompensated heart failure. SCORED, Sanofi Lexicon, Chair [16] RCT of sotagliflozin versus placebo in patients with diabetes and at high cardiovascular risk.
Sotagliflozin, sold under the brand name Inpefa among others, is a medication used to reduce the risk of death due to heart failure. [1] It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. [1]
Heart failure has historically been irreversible, but a new study suggests that could change. At the University of Utah, scientists used a new gene therapy that reversed heart failure in animals.
Diabetic cardiomyopathy is a disorder of the heart muscle in people with diabetes.It can lead to inability of the heart to circulate blood through the body effectively, a state known as heart failure(HF), [2] with accumulation of fluid in the lungs (pulmonary edema) or legs (peripheral edema).
Ads
related to: dapagliflozin role in heart failure